

BIOMÉRIEUX

DON'T LET THEM MISS A **SMILE.**

BIOFIRE® Syndromic PCR Testing for Infectious Diseases in Children



PIONEERING DIAGNOSTICS



Diagnosing a sick child can be a challenge.

Pediatric patients can't always tell you their symptoms. The BIOFIRE® Panels utilize a syndromic approach—simultaneously testing for different pathogens that can cause similar symptoms. In about an hour, you'll have the actionable results you need to help put your patients, and their concerned caregivers, at ease.

7 Panels. 175+ Targets. ~1 Hour.



**BIOFIRE®
RESPIRATORY 2.1 PLUS PANEL†**
23 Targets. ~45 Minutes.



**BIOFIRE®
BLOOD CULTURE IDENTIFICATION 2 PANEL*†**
43 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
GASTROINTESTINAL PANEL*†**
22 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
MENINGITIS/ENCEPHALITIS PANEL*†**
14 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
PNEUMONIA PLUS PANEL†**
34 Targets. ~1 Hour.



**BIOFIRE®
JOINT INFECTION PANEL*†**
39 Targets. ~1 Hour.



**BIOFIRE® FILMARRAY®
TROPICAL FEVER PANEL*†**
6 Targets. ~50 Minutes.

* FDA cleared

† CE 2797

Identify more clinically relevant pathogens.

Compared to standard of care, syndromic testing can detect more clinically relevant pathogens that make pediatric patients sick.

Here are some examples of clinical evidence using BIOFIRE® Panels:



**BIOFIRE® FILMARRAY®
MENINGITIS/
ENCEPHALITIS PANEL**



4x

Diagnostic yield
for bacterial pathogens¹



2.8x

Diagnostic yield
for viruses²



**BIOFIRE®
RESPIRATORY 2.1 PLUS
PANEL**



57%

Diagnostic yield
when compared to
microbiological rate³



**BIOFIRE® FILMARRAY®
GASTROINTESTINAL
PANEL**

11%

Standard-of-care
methods

vs

40%

BIOFIRE FILMARRAY
GI Panel⁴



**BIOFIRE® FILMARRAY®
PNEUMONIA PLUS
PANEL**

12%

In CAP cases with
standard-of-care
methods

vs

67%


In CAP cases with the
BIOFIRE FILMARRAY
PNplus Panel⁵



Shorten the time to diagnosis.

With just two minutes hands-on time and about an hour turnaround time, syndromic testing can significantly reduce the time to actionable results compared to standard of care in pediatric hospitals.

Here are some examples of clinical evidence using BIOFIRE® Panels:




Provide faster optimal therapy to your pediatric patients.

Syndromic testing has shown a significant decrease in time to optimal therapy in pediatric patients.

Here are some examples of clinical evidence using BIOFIRE® Panels:



**BIOFIRE® FILMARRAY®
GASTROINTESTINAL
PANEL**



35 hrs
Standard-of-care
methods


VS



11 hrs
**BIOFIRE FILMARRAY
GI Panel⁴**



**BIOFIRE®
BLOOD CULTURE
IDENTIFICATION 2 PANEL**



60 hrs
Standard-of-care
methods


VS



27 hrs
BIOFIRE BCID2 Panel^{9*}



**BIOFIRE® FILMARRAY®
MENINGITIS/
ENCEPHALITIS PANEL**



28 hrs
Standard-of-care
methods

VS



18 hrs
**BIOFIRE FILMARRAY
ME Panel¹⁰**

*Data obtained with the previous version of the BIOFIRE BCID2 Panel.



Improve your patient management.



Syndromic testing results when combined with appropriate antimicrobial stewardship (AMS) interventions can help inform patient management decisions like stopping or altering therapy, reducing length of stay (LOS), or moving the patient into or out of isolation.

Here are some examples of clinical evidence using BIOFIRE® Panels:



**BIOFIRE® FILMARRAY®
GASTROINTESTINAL
PANEL**



23%
of pediatric patients
received revised medical
management^{††}



36%
reduction
in antibiotic use¹²



**BIOFIRE® FILMARRAY®
PNEUMONIA PLUS
PANEL**



60%
of pediatric patients had
a change in antibiotics⁸



**BIOFIRE® FILMARRAY®
MENINGITIS/
ENCEPHALITIS PANEL**



8.8-day
LOS reduction^{1*}



**BIOFIRE®
BLOOD CULTURE
IDENTIFICATION 2 PANEL**



Children could be discharged earlier
compared to standard-of-care methods^{13†}

*When pathogen was identified.

†Data obtained with the previous version of the BIOFIRE BCID2 Panel.

Reduce unnecessary testing and procedures.

Using a syndromic approach to test for a broad grouping of probable pathogens, syndromic testing can reduce unnecessary testing in pediatric patients, like repeat lumbar punctures, chest radiographs, and imaging studies.

Here are some examples of clinical evidence using BIOFIRE® Panels:



**BIOFIRE® FILMARRAY®
MENINGITIS/
ENCEPHALITIS PANEL**




15.1%

Decrease in lumbar punctures where a clinical guideline was in place plus mPCR* testing using the BIOFIRE FILMARRAY ME and RP Panels.¹⁴



**BIOFIRE®
RESPIRATORY 2.1 PLUS
PANEL**




59%

Reduction in ordering chest x-rays¹⁵



**BIOFIRE® FILMARRAY®
GASTROINTESTINAL
PANEL**



Up to
53%

Reduction in use of imaging studies^{16,17}



**BIOFIRE®
BLOOD CULTURE
IDENTIFICATION 2 PANEL**



21%

Fewer repeat blood cultures among inpatients^{18†}

*mPCR=multiplex polymerase chain reaction †Data obtained with the previous version of the BIOFIRE BCID2 Panel.

Increase confidence with accurate results.

The following BIOFIRE® Panels are either FDA cleared and/or CE marked. BIOFIRE technology is based on nested multiplex PCR results with high sensitivity and specificity.



BIOFIRE® RESPIRATORY 2.1 PLUS PANEL†

Overall Performance: 97.1% sensitivity, 99.3% specificity¹⁹
SARS-CoV-2 Performance: 98.4% PPA, 98.9% NPA²⁰



BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 PANEL*†

99.0% sensitivity, 99.7% specificity²¹



BIOFIRE® FILMARRAY® GASTROINTESTINAL PANEL*†

98.7% sensitivity, 99.2% specificity²²



BIOFIRE® FILMARRAY® MENINGITIS/ENCEPHALITIS PANEL*†

94.2% sensitivity, 99.8% specificity²³



BIOFIRE® FILMARRAY® PNEUMONIA PLUS PANEL†

BAL-like: 96.2 % sensitivity, 98.4% specificity²⁴
Sputum-like: 96.3% sensitivity, 97.4% specificity²⁴



BIOFIRE® JOINT INFECTION PANEL*†

91.7% sensitivity, 99.8% specificity²⁵



BIOFIRE® FILMARRAY® TROPICAL FEVER PANEL*†

95.1% sensitivity, 99.8% specificity^{26,27}



* FDA cleared

† CE₂₇₉₇

Introducing the BIOFIRE® FILMARRAY® Tropical Fever (TF) Panel, the latest syndromic panel from bioMérieux.

Malaria, chikungunya, dengue and leptospirosis affect 100+ countries and are estimated to cause more than 300 million infections per year resulting in more than 600,000 deaths.²⁸⁻³¹

These tropical fever infections often present with overlapping, non-specific signs and symptoms, making them challenging to diagnose. Their prevalence is expected to rise around the world as the impact of global climate change leads to conditions favorable to the spread of these diseases.³²

Molecular syndromic testing with the BIOFIRE FILMARRAY TF Panel cuts through diagnostic complexities by simultaneously testing 6 targets in about 50 minutes using a single test to provide answers in a clinically actionable timeframe. This may enable faster time to effective therapy and a reduction in unnecessary treatment.



**BIOFIRE® FILMARRAY®
TROPICAL FEVER
PANEL**

BIOFIRE syndromic testing can improve pediatric care.

BIOFIRE® Panels can make a significant impact on pediatric patient care. Syndromic testing provides accurate, reliable results that can alleviate anxiety for parents and providers.



**ADD THE BIOFIRE PANELS TO YOUR
PEDIATRIC WORKFLOW TODAY.**



References



1. Park SE, *et al.*, (2021) Brain Dev. 43(2):234-243.
2. Hagen A, *et al.*, (2020) BMC Pediatr. 20(1):56.
3. Kitano T., *et al.*, (2020) J Infect Chemother. 26(1):82-85.
4. Cotter JM, *et al.*, (2021) Pediatrics. 147(5).
5. Yen, T. Y., *et al.*, (2023). J Med Virol 95(1): e28334.
6. O'Brien MP, *et al.*, (2018) Pediatr Infect Dis J. 37(9):868-871.
7. Subramony A, *et al.*, (2016) J Pediatr. 173:196-201.
8. Fireizen Y, *et al.*, (2022) J Pediatr Intensive Care, DOI: 10.1055/s-0042-1743178
9. Messacar K, *et al.*, (2017) J Pediatric Infect Dis Soc. Sep 1;6(3):267-274.
10. Posnakoglou L, *et al.*, (2020) Eur J Clin Microbiol Infect Dis. 39(12):2370-2386.
11. Truong J, *et al.*, (2022) Arch Dis Child. 107(6):601-605.
12. Yoo IH, *et al.*, (2021) Diagnostics (Basel). 11(7):1175.
13. Ray STJ, *et al.*, (2016) Pediatr Infect Dis J. May;35(5).
14. Crook J, *et al.*, (2020) Infect Control Hosp Epidemiol. Nov; 41(11):1285-1291.
15. Echavarria M, *et al.*, (2018) J Clin Virol. Nov;108:90-95.
16. Beal SG, *et al.*, (2017) J Clin Microbiol. Dec 26;56(1).
17. Axelrad JE, *et al.*, (2019) J Clin Microbiol. Feb 27;57(3).
18. Hughes J, *et al.*, (2021) Hosp Pediatr. 2021 May;11(5):472-477.
19. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Respiratory 2 *plus* Panel, data on file, BioFire Diagnostics.
20. Overall performance based on prospective SARS-CoV-2 clinical study for the BIOFIRE® Respiratory 2.1 *plus* Panel in comparison to 3 EUA tests, data on file, BioFire Diagnostics.
21. Overall performance is the aggregate of the prospective, archived, and seeded data from the clinical studies. Data on file, BioFire Diagnostics.
22. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Gastrointestinal Panel, data on file, BioFire Diagnostics.
23. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel, data on file, BioFire Diagnostics.
24. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Pneumonia *plus* Panel, data on file, BioFire Diagnostics.
25. Overall performance based on prospective clinical study for the BIOFIRE® Joint Infection Panel, data on file, BioFire Diagnostics.
26. Manabe Y, Betz J, Jackson O, Asoala V, Bazan I, Blair P, *et al.* Clinical evaluation of the BioFire Global Fever Panel for the identification of malaria, leptospirosis, chikungunya, and dengue from whole blood: a prospective, multicentre, cross-sectional diagnostic accuracy study. Lancet Infect Dis. 2022;22(9):1356-1364.
27. Performance claims are based on DEN200043 (De Novo) Global Fever Panel Clinical Studies (on file at bioMérieux).
28. World Health Organization. World Malaria Report 2024.
29. Bhatt S, Gething P, Brady O, Messina J, Farlow A, Moyes C, *et al.* The global distribution and burden of dengue. Nature. 2013;496(7446): 504-507.
30. Costa M, Hagan J, Calcagno J, Kane M, Torgerson P, Matinez-Silveira M, *et al.* Global Morbidity and Mortality of Leptospirosis: A Systematic Review. PLoS Negl Trop Dis. 2015;9(9):e0003898.
31. de Souza W, Ribeiro G, de Lima S, de Jesus R, Moreira F, Whittaker C, *et al.* Chikungunya: a decade of burden in the Americas. Lancet Reg Health Am. 2024;30:100673.
32. Liao H, Lyon C, Ying B, Hu T. Climate change, its impact on emerging infectious diseases and new technologies to combat the challenge. Emerg Microbes Infect. 2024;13(1): 2356143.

Contact Us

bioMérieux S.A.
69280 Marcy l'Etoile
France
Tel: +33 (0) 4 78 87 20 00
biomerieux.com

Manufactured by:
BIOFIRE Diagnostics, LLC
515 Colorow Drive
Salt Lake City, UT 84108 USA
Tel: +1-801-736-6354

Product availability varies by country. Please contact your local bioMérieux representative for details.



*“Syndromic testing
has changed the way
I practice medicine.”*

- Dr Jaime Fergie, MD, FAAP, FIDSA
Director of Pediatric Infectious Diseases
Driscoll Children's Hospital, Texas, USA

